Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your phone could help doctors prescribe better: app tracks symptoms in real time

NCT ID NCT04248517

Knowledge-focused Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether a smartphone app can help doctors and patients make better medication choices for first-episode psychosis. Participants use the app to report symptoms and functioning in real time, giving clinicians up-to-date information to guide shared decisions. The goal is to maximize benefits, minimize side effects, and improve treatment satisfaction. The trial enrolled 23 people aged 16 to 30 who were new to the OnTrackNY program.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mHealth smartphone app
What this could lead to
If successful, this approach could help doctors and patients work together to fine-tune medication, improving satisfaction and reducing side effects.
What could go wrong
This is a small, early-stage study with only 23 participants, so results may not apply broadly. The app relies on user engagement, which can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Oct 2020

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female OnTrackNY participants, ages 16 to 30, of any race/ethnicity * Able and willing to give informed consent and participate in the intervention * Participating in OnTrackNY for less than 1 year because this group may be more in need of medication adjustments and will be less likely to graduate from the program before 6 months of participation. Exclusion Criteria: * Suicidal at baseline with C-SSRS score 4 or 5. * PANSS baseline score of 5 (moderately severe) or greater on the Conceptual Disorganization item (P2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for First episode psychosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

First episode psychosis Schizophrenia

Contacts and locations

Locations

  • Bestself Behavioral Health, Inc.

    Buffalo, New York, 14202, United States

  • Institute for Family Health

    New York, New York, 10453, United States

  • Lenox Hill Hospital

    New York, New York, 10065, United States

  • Washington Heights Community Service

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.